Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMS 2022 | Current & emerging biomarkers in multiple myeloma

Noemí Puig • 26 Aug 2022
IMS 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

Noemi Puig, MD, PhD, University Hospital Salamanca, Salamanca, Spain, outlines current and emerging biomarkers used at diagnosis in multiple myeloma, highlighting the potential of circulating tumor plasma cells as a prognostic factor in both smoldering myeloma and multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Noemí Puig

Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
2:17
Methods for using mass spectrometry in the PB versus MRD in the bone marrow in multiple myeloma
Noemí Puig • 18 Sep 2025
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
3:49
Evidence supporting the use of MRD-guided treatment in multiple myeloma: GEM2014MAIN and AURIGA
Noemí Puig • 18 Sep 2025
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
2:20
Investigating the use of mass spectrometry & NGF to measure MRD and predict outcomes in HR-SMM
Noemí Puig • 7 Oct 2024
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice
1:49
The value of mass spectrometry in multiple myeloma & how this may impact clinical practice
Noemí Puig • 7 Oct 2024

Related Videos

Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
4:13
Impact of Duffy status on PFS in newly diagnosed multiple myeloma treated with RVd ± autoSCT
Noemí Puig • 7 Dec 2025
Key multiple myeloma breakthroughs at ASH 2025
6:04
Key multiple myeloma breakthroughs at ASH 2025
Noemí Puig • 7 Dec 2025
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
4:18
A dual-targeting BCMA and CD19 FasTCAR-T (GC012F/AZD0120) as 1L therapy for newly diagnosed myeloma
Noemí Puig • 7 Dec 2025
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
2:29
Ultra-deep WGS of cell-free DNA to detect bone marrow-derived mutations in multiple myeloma
Noemí Puig • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals